Search research articles
Contact Us
Filters
Showing results (131-140 of 139) with videos related to
Page
of 14
Sort By:
You have reached the last page of results.
This site can display upto 139 results.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 4, 2021
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
Yoon-Koo Kang, Satoshi Morita, Taroh Satoh, et al.
Nature Communications
|
May 11, 2026
All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer
Ching-Fei Li, Yongkun Wei, Heng-Huan Lee, et al.
The New England Journal of Medicine
|
May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Kohei Shitara, Elena Elimova, Tianshu Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study
Marc Pelletier, Jie Yang, Mukta Joshi, et al.
The Lancet. Oncology
|
September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Juan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
Herui Yao, Min Yan, Zhongsheng Tong, et al.
International Journal of Hematology
|
February 25, 2022
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan
Wen-Li Hwang, Tsung-Chih Chen, Hsuan-Yu Lin, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
May 18, 2026
Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines
Chih-Chieh Yen, I-Chen Wu, Cheng-Chan Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
James J Harding, Do-Youn Oh, Teresa Macarulla Mercade, et al.
Page
of 14
Search research articles
Search
Showing results (131-140 of 139) with videos related to
Sort By:
Page
of 14
You have reached the last page of results.
This site can display upto 139 results.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
September 4, 2021
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
Yoon-Koo Kang, Satoshi Morita, Taroh Satoh, et al.
Nature Communications
|
May 11, 2026
All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer
Ching-Fei Li, Yongkun Wei, Heng-Huan Lee, et al.
The New England Journal of Medicine
|
May 27, 2026
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
Kohei Shitara, Elena Elimova, Tianshu Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study
Marc Pelletier, Jie Yang, Mukta Joshi, et al.
The Lancet. Oncology
|
September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study
Juan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
Herui Yao, Min Yan, Zhongsheng Tong, et al.
International Journal of Hematology
|
February 25, 2022
NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan
Wen-Li Hwang, Tsung-Chih Chen, Hsuan-Yu Lin, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
May 18, 2026
Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines
Chih-Chieh Yen, I-Chen Wu, Cheng-Chan Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations
James J Harding, Do-Youn Oh, Teresa Macarulla Mercade, et al.
Page
of 14